{"entity":{"id":"nct05623267","kind":"trial","name":"Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT","aka":["SURPASS"],"tldr":"A phase 2/3 trial of sugemalimab in lung cancer, run by Sun Yat-sen University, now recruiting.","summary":"Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT is a phase 2/3, randomised interventional study registered as NCT05623267 by Sun Yat-sen University, with a registry enrolment figure of 346 participants, started 2023-07-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: Sugemalimab; Placebo. Conditions listed: Limited Stage Small Cell Lung Cancer. Primary outcome: Progress Free Survival(PFS). Lung eligibility wording from the registry: \"2、Histologically or cytologically confirmed small cell lung cancer\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05623267","url":"https://clinicaltrials.gov/study/NCT05623267"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["limited-stage-sclc"],"sections":[],"technologies":["checkpoint-inhibitor","imrt-igrt"],"targets":[],"drugs":["sugemalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05623267","phase":"2/3","setting":"A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy","sponsor":"Sun Yat-sen University","enrolled":346,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05623267/","neighbours":{"cancer":[{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"sugemalimab","kind":"drug","name":"Sugemalimab","route":"/drugs/sugemalimab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}